SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-009236
Filing Date
2023-03-22
Accepted
2023-03-22 17:27:19
Documents
14
Period of Report
2023-03-22
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tpst-20230322.htm   iXBRL 8-K 57853
2 EX-99.1 tpst-ex99_1.htm EX-99 211501
3 GRAPHIC img73128808_0.jpg GRAPHIC 34814
  Complete submission text file 0000950170-23-009236.txt   443311

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tpst-20230322.xsd EX-101.SCH 2472
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tpst-20230322_lab.xml EX-101.LAB 12806
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tpst-20230322_pre.xml EX-101.PRE 9455
8 EXTRACTED XBRL INSTANCE DOCUMENT tpst-20230322_htm.xml XML 4533
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

IRS No.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 23753818
SIC: 2834 Pharmaceutical Preparations